SK IE Technology Sells China Plant, Halts Jeungpyeong Production to Refocus on Europe and North America

COMPANY / Reporter Kim Jisun / 2026-05-28 05:12:28

An employee of SK IE Technology examines a battery separator. 

(Photo = SK IE Technology)

 

 

[Alpha Biz= Kim Jisun] SK IE Technology (SKIET) has announced plans to sell its China plant and halt commercial production at its Jeungpyeong facility, as part of a strategic shift toward Europe and North America.

The company disclosed on May 27 that it will sell its entire stake in its Chinese subsidiary, SK Hi-Tech Battery Materials (Jiangsu), to a Chinese separator manufacturer for approximately KRW 88.8 billion (CNY 400 million). The move will effectively end production of China-based separators that have faced challenges in overseas sales.

SKIET also plans to cease commercial operations at its Jeungpyeong plant within the year, citing aging facilities and declining economic efficiency. The site is expected to be repurposed as an R&D hub for next-generation separator materials and prototype testing.

Going forward, the company will center its separator production in Poland, where it has been expanding capacity. With multiple plants under development, total annual production capacity in Poland is expected to reach 1.54 billion square meters—enough to supply batteries for approximately 1.75 million electric vehicles.

SKIET said the restructuring aims to optimize its supply chain, reduce fixed costs, and improve utilization rates, enabling more efficient response to growing electric vehicle demand in Europe and North America.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

National Pension Service to Decide Domestic Equity Allocation, Market Awaits Impact
Hyundai Motor Sales Decline in China Amid EV Shift, Eyes Rebound with Localized EV Strategy
Shareholder Group Opposes Samsung Electronics’ Profit-Linked Bonus Plan, Citing Potential Legal Violations
Investors Must Sell U.S. Stocks by Early Morning KST to Qualify for Full Tax Deduction Under RIA Scheme
Bukwang Pharmaceutical Becomes Largest Shareholder of Korea Union Pharmaceutical Following Restructuring Deal
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

SNS